Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002

被引:48
作者
Kern, WV
Steib-Bauert, M
de With, K
Reuter, S
Bertz, H
Frank, U
von Baum, H
机构
[1] Univ Hosp, Ctr Infect Dis & Travel Med, Dept Med, D-79106 Freiburg, Germany
[2] Univ Hosp, Dept Haematol Oncol, D-79106 Freiburg, Germany
[3] Univ Hosp, Inst Environm Med & Hosp Epidemiol, D-79106 Freiburg, Germany
[4] Univ Ulm, Univ Hosp & Med Ctr, Dept Haematol Oncol, Ulm, Germany
[5] Univ Ulm, Dept Med Microbiol & Hyg, Sect Hosp Hyg, Ulm, Germany
关键词
antibiotic use; Escherichia coli; fluoroquinolone resistance; antibiotic policy; drug utilization; febrile neutropenia; resistance epidemiology; staphylococci;
D O I
10.1093/jac/dkh510
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To compare rates of in vitro fluoroquinolone resistance of bacterial isolates obtained from inpatients of two haematology-oncology services with high and low fluoroquinolone consumption. Methods: Two hospitals with consistently high (A) and low (B) fluoroquinolone use in their haematology-oncology services between the years 1999 and 2002 were identified in a hospital antibiotic use surveillance project. Rates of in vitro resistance to fluoroquinolones in inpatients of the services were determined for Escherichia coli and coagulase-negative staphylococcal bloodstream isolates, and also for Pseudomonas aeruginosa and Staphylococcus aureus isolates from any site. Results: Fluoroquinolone resistance of E. coli was significantly higher in hospital A than in hospital B, but there was no such correlation between fluoroquinolone use and resistance rates for P. aeruginosa and staphylococci. Conclusion: The impact of antibiotic consumption on the prevalence of resistance may differ widely between different pathogens. Interventions using ecological analyses of the relationship between hospital antibiotic use and resistance need to consider pathogen-specific dynamics in the emergence and control of bacterial resistance.
引用
收藏
页码:57 / 60
页数:4
相关论文
共 29 条
[1]   Trends in bacterial resistance to fluoroquinolones [J].
Acar, JF ;
Goldstein, FW .
CLINICAL INFECTIOUS DISEASES, 1997, 24 :S67-S73
[2]   Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis:: clinical consequences [J].
Aparicio, JR ;
Such, J ;
Pascual, S ;
Arroyo, A ;
Plazas, J ;
Girona, E ;
Gutiérrez, A ;
de Vera, F ;
Palazón, JM ;
Carnicer, F ;
Pérez-Mateo, M .
JOURNAL OF HEPATOLOGY, 1999, 31 (02) :277-283
[3]   DANMAP: monitoring antimicrobial resistance in Denmark [J].
Bager, F .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 14 (04) :271-274
[4]  
BAQUERO F, 1990, EUR UROL, V17, P3
[5]   The use of antimicrobials in ten Australian and New Zealand intensive care units [J].
Bellomo, R ;
Bersten, AD ;
Boots, RJ ;
Bristow, PJ ;
Dobb, GJ ;
Finfer, SR ;
McArthur, CJ ;
Richard, B ;
Skowronski, GA .
ANAESTHESIA AND INTENSIVE CARE, 1998, 26 (06) :648-653
[6]   Conventional and molecular epidemiology of trimethoprim-sulfamethoxazole resistance among urinary Escherichia coli isolates [J].
Burman, WJ ;
Breese, PE ;
Murray, BE ;
Singh, KV ;
Batal, HA ;
MacKenzie, TD ;
Ogle, JW ;
Wilson, ML ;
Reves, RR ;
Mehler, PS .
AMERICAN JOURNAL OF MEDICINE, 2003, 115 (05) :358-364
[7]   Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis [J].
Carratala, J ;
FernandezSevilla, A ;
Dominguez, FTMA ;
Gudiol, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (02) :503-505
[8]   Antibiotic use in Germany and Europe [J].
de With, K ;
Schröder, H ;
Meyer, E ;
Nink, K ;
Hoffmann, S ;
Steib-Bauert, M ;
Kämmerer, R ;
Ruess, S ;
Daschner, FD ;
Kern, WV .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2004, 129 (38) :1987-1992
[9]  
Delarive P, 2000, SCHWEIZ MED WSCHR, V130, P1837
[10]  
DEWITH K, 2004, CLIN MICROBIOLOGY S3, V10, P326